Janney Montgomery Scott LLC lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Rating) by 1.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,565 shares of the company’s stock after selling 1,938 shares during the period. Janney Montgomery Scott LLC’s holdings in Takeda Pharmaceutical were worth $1,434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Mondrian Investment Partners LTD grew its stake in Takeda Pharmaceutical by 10.0% in the second quarter. Mondrian Investment Partners LTD now owns 4,751,715 shares of the company’s stock valued at $66,524,000 after purchasing an additional 432,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Takeda Pharmaceutical by 13.7% in the first quarter. Goldman Sachs Group Inc. now owns 4,242,689 shares of the company’s stock valued at $60,755,000 after purchasing an additional 509,886 shares during the last quarter. Bank of America Corp DE grew its stake in Takeda Pharmaceutical by 7.3% in the first quarter. Bank of America Corp DE now owns 3,387,908 shares of the company’s stock valued at $48,515,000 after purchasing an additional 231,268 shares during the last quarter. BlackRock Inc. grew its stake in Takeda Pharmaceutical by 38.6% in the first quarter. BlackRock Inc. now owns 3,021,274 shares of the company’s stock valued at $43,265,000 after purchasing an additional 842,139 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Takeda Pharmaceutical by 41.9% during the second quarter. Renaissance Technologies LLC now owns 2,828,300 shares of the company’s stock worth $39,709,000 after acquiring an additional 835,100 shares during the last quarter. Hedge funds and other institutional investors own 2.05% of the company’s stock.
Takeda Pharmaceutical Price Performance
Shares of TAK stock opened at $16.10 on Tuesday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.28 and a fifty-two week high of $16.13. The firm has a market capitalization of $49.92 billion, a price-to-earnings ratio of 29.82 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 1.15. The stock’s 50-day simple moving average is $14.89 and its 200-day simple moving average is $14.08.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.
- Get a free copy of the StockNews.com research report on Takeda Pharmaceutical (TAK)
- Michael Burry is Bearish on Stocks Again and Heres Why
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.